Singh, Gurmukh Arinze, Nkechi Manthei, David M Plapp, Frederick V Bollag, Roni J
Published in
Laboratory medicine
Immunoglobulin monoclonal light chains (MLCs) in serum and urine are markers for monoclonal gammopathy and could serve as markers of minimal residual disease (MRD) in multiple myeloma (MM). Excretion of MLCs in urine is known to result in renal damage and shorter survival in patients with LC-predominant MM. Retrospective review of urine immunofixat...
Sowa, Ireneusz Mołdoch, Jarosław Paduch, Roman Strzemski, Maciej Szkutnik, Jacek Tyszczuk-Rotko, Katarzyna Dresler, Sławomir Szczepanek, Dariusz Wójciak, Magdalena
Published in
Molecules (Basel, Switzerland)
Carlina acaulis is highly valued in the traditional medicine of many European countries for its diuretic, cholagogue, anthelmintic, laxative, and emetic properties. Moreover, practitioners of natural medicine indicate that it has anti-cancer potential. However, its phytochemistry is still little known. In the present study, the polyphenolic composi...
Jiménez-Ubieto, Ana Martín-Muñoz, Alejandro Poza, María Dorado, Sara García-Ortiz, Almudena Revilla, Enrique Sarandeses, Pilar Ruiz-Heredia, Yanira Baumann, Tycho Rodríguez, Antonia
...
Published in
Frontiers in Immunology
Varettoni, Marzia Zibellini, Silvia Merli, Michele Drandi, Daniela Jiménez, Cristina Furlan, Daniela Ferretti, Virginia Valeria Fabbri, Nicole Dogliotti, Irene Varraso, Chiara
...
Published in
Hematological oncology
Yan, Xing Liu, Changhong
Published in
Tumori
Lung cancer is one of the most malignant cancers in China with a rising incidence rate. Despite the fact that surgical treatment is the only possible cure for lung cancer, its long-term efficacy is compromised by the high level of postoperative local recurrence rate. Minimal residual disease is the leading cause of tumor recurrence, yet the suggest...
D’Agostino, Mattia Terragna, Carolina van Duin, Mark
Published in
Frontiers in Oncology
Zhou, Ting Karrs, Jeremiah Ho, Truc Doverte, Alyssa Kochenderfer, James N Shah, Nirali N Yuan, Constance M Wang, Hao-Wei
Published in
Cytometry. Part B, Clinical cytometry
Multiparametric flow cytometry (MFC) has become a powerful tool in minimal residual disease (MRD) detection in B-lymphoblastic leukemia/lymphoma (B-ALL). In the setting of targeted immunotherapy, B-ALL MRD detection often relies on alterative gating strategies, such as the utilization of CD22 and CD24. It is important to depict the full diversity o...
McMillan, Annabel Tran, Thien-An Galas-Filipowicz, Daria Camilleri, Marquita Lecat, Catherine Ainley, Louise Guo, Yanping Yong, Kwee Sive, Jonathan
Published in
Cytometry. Part B, Clinical cytometry
Achieving minimal residual disease (MRD) negativity following treatment for multiple myeloma (MM) is associated with improved progression free and overall survival. In the UK, MRD assessments in MM are not incorporated into routine clinical use outside trials. Widely used in other haematological malignancies, there is a role for widening the availa...
Niu, Jianli Kim, Myeongji Jalal, Ayesha T Goldberg, Jessica E Acevedo Martinez, Elsa M Suarez Moscoso, Nathalie P Rubio-Gomez, Heysu Mayer, Daniel Visbal, Alvaro Sareli, Candice
...
Published in
Healthcare (Basel, Switzerland)
The COVID-19 Omicron variant has imposed a tremendous burden on healthcare services. We characterized the types of the Omicron variant-associated hospitalizations and their associations with clinical outcomes. Consecutive adults hospitalized with COVID-19 during the Omicron variant surge period of 1-14 January 2022, were classified into one of thre...
Jiménez-Ubieto, Ana Martín-Muñoz, Alejandro Poza, María Dorado, Sara García-Ortiz, Almudena Revilla, Enrique Sarandeses, Pilar Ruiz-Heredia, Yanira Baumann, Tycho Rodríguez, Antonia
...
Published in
Frontiers in Immunology
Background CART therapy has produced a paradigm shift in the treatment of relapsing FL patients. Strategies to optimize disease surveillance after these therapies are increasingly necessary. This study explores the potential value of ctDNA monitoring with an innovative signature of personalized trackable mutations. Method Eleven FL patients treated...
